Synthesis and in vitro antimicrobial and antitumoral screening of novel lipophilic isoniazid analogues. VI

Bollettino Chimico Farmaceutico

Volumn 137, Issue 7, 1998, Pages 267-276

  Vigorita, M G ^a   Ottana R ^a   Maccari, R ^a   Monforte, F ^a   Bisignano, G ^a   Pizzimenti, F C ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antimicrobial; Antineoplastic screening; CF3 group; Cyanohoranes; Isoniazid analogues; Lipophilicity

Indexed keywords

DRUG ANALOG; ISONIAZID DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NONHUMAN; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; TUMOR CELLS, CULTURED;

EID: 0345404436     PISSN: 00066648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. th edition, J. Wiley and Sons Inc., pp. 575-635 (1996).
2. Inderlied C.B., Kemper C.A., Bermudez L.E.M., Clin. Microb. Rev. 6, 266-310 (1993).
3. Ellner J.J., Goldberger M.J., J. Infect. Dis. 163, 1326-1335 (1991).
4. th edition, McGraw-Hill Companies Inc., New York, pp.1155-1174, (1996).
5. a) Rastogi N., Moreau B., Capmau M.L., Goh K.S., David H.L., Zbl. Bakt. Hyg. A 268, 456-462 (1988);
6. b) Rastogi N., Goh K.S., Antimicrob. Agents Chemother. 34, 2061-2064 (1990).
7. a) Vigorita M.G., Ottanà R., Zappalà C., Maccari R., Pizzimenti F.C., Gabbrielli G., Il Farmaco 49, 775-781 (1994);
8. b) Vigorita M.G., Ottanà R., Zappalà C., Maccari R., Pizzimenti F.C., Gabbrielli G., Il Farmaco 50, 783-786 (1995).
9. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., David H.L., Antimicrob. Agents Chemother. 20, 666-677 (1981).
10. a) Ottanà R., Maccari R., Vigorita M.G., Rotondo E., First Italian-Swiss Meeting on Medicinal Chemistry, 23-26 September 1997, Torino (Italy), p. 182;
11. b) Ottanà R., Maccari R., Vigorita M.G., Rotondo E., J. Chem. Res. 16, (1998).
12. a) Tomlison E., J. Chromat. 113, 1-45 (1975);
13. b) Kaliszan R., J. Chromat. 220, 71-83 (1981).
14. Ottanà R., Maccari R., Vigorita M.G., J. Chem. Res.(S) 12, 496-497 (1994).
15. a) Fox H.H., Gibas J.T., J. Org. Chem. 18, 983-989 (1953);
16. b) Mcmillan F.H., Leonard F., Meltzer R.I., King J.A., J. Am. Pharm. Ass. Sc. Ed. 42, 457-464 (1953).
17. Inderlied C.B., "Antibiotics in Laboratory Medicine", 3rd edition, Lorian V.M.D. Editor, Williams & Wilkins, Baltimore, pp.134-172, (1991),.
18. Sahm D.F., Washington J.A. "Manual of Clinical Microbiology", Ed. by Balows W., Hausler Jr. J., Herman K.L., Shadomy H.J., American Society for Microbiology, Washington, pp. 1105-1116, (1991).
19. Boyd M.R., Principles & Practices of Oncology 3, 1-12 (1989).
20. a) Hall I. H., Spielvogel B. F., Sood A., Ahmed F., Jafri S., J. Pharm. Sci. 76, 359-365 (1987);
21. b) Sood A., Sood C. K., Spielvogel B. F., Hall I. H., Eur. J. Med. Chem. 25, 301-308 (1990);
22. c) Spielvogel B. F., Sood A., Morse K. W., Wong O. T., Hall I. H., Pharmazie 46, 592-594 (1991);
23. Sood C. K., Sood A., Spielvogel B. F., Yousef J. A., Burnham B., Hall I. H., J. Pharm. Sci. 80, 1133-1140 (1991).
24. a) Mills W.J., Sutton C.H., Libby E., Todd L.J., Inorg. Chem. 29, 302-308 (1990);
25. b) Spielvogel B.F., Ahmed F.U., Morse K.W., McPhail A.T., Inorg. Chem. 23, 1776-1777 (1984);
26. c) Lane C.F., Synthesis 135-146 (1975) and references cited herein.
27. Masuda N., Sakagaua E., Ohya S., Antimicrob. Agents Chemother. 39, 645-649 (1995).
28. Weislow O.W., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R., J. Natl. Cancer Inst. 81, 577-586 (1989).